CN118843624A - 结晶的咪唑并[4,5-b]吡啶化合物、药物组合物以及它们在治疗医学病况中的应用 - Google Patents

结晶的咪唑并[4,5-b]吡啶化合物、药物组合物以及它们在治疗医学病况中的应用 Download PDF

Info

Publication number
CN118843624A
CN118843624A CN202280087913.4A CN202280087913A CN118843624A CN 118843624 A CN118843624 A CN 118843624A CN 202280087913 A CN202280087913 A CN 202280087913A CN 118843624 A CN118843624 A CN 118843624A
Authority
CN
China
Prior art keywords
compound
imidazo
benzyl
pyrazol
oxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280087913.4A
Other languages
English (en)
Chinese (zh)
Inventor
B·罗伯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CN118843624A publication Critical patent/CN118843624A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202280087913.4A 2021-11-12 2022-11-11 结晶的咪唑并[4,5-b]吡啶化合物、药物组合物以及它们在治疗医学病况中的应用 Pending CN118843624A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21207942.0 2021-11-12
EP21207942.0A EP4180428A1 (en) 2021-11-12 2021-11-12 Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions
PCT/US2022/049695 WO2023086564A1 (en) 2021-11-12 2022-11-11 Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions

Publications (1)

Publication Number Publication Date
CN118843624A true CN118843624A (zh) 2024-10-25

Family

ID=78617277

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280087913.4A Pending CN118843624A (zh) 2021-11-12 2022-11-11 结晶的咪唑并[4,5-b]吡啶化合物、药物组合物以及它们在治疗医学病况中的应用

Country Status (10)

Country Link
US (3) US11814383B2 (https=)
EP (2) EP4180428A1 (https=)
JP (1) JP2024543413A (https=)
CN (1) CN118843624A (https=)
AU (1) AU2022387516A1 (https=)
CA (1) CA3237156A1 (https=)
IL (1) IL312625A (https=)
MX (1) MX2024005766A (https=)
TW (1) TW202334143A (https=)
WO (1) WO2023086564A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI731317B (zh) * 2013-12-10 2021-06-21 美商健臻公司 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑
EP4180428A1 (en) 2021-11-12 2023-05-17 Genzyme Corporation Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions
CN121464134A (zh) * 2023-05-17 2026-02-03 中枢疗法公司 咪唑并[4,5-b]吡啶化合物的颗粒、药物组合物及其在治疗医学病症中的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI731317B (zh) 2013-12-10 2021-06-21 美商健臻公司 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑
EA201791336A1 (ru) 2014-12-18 2017-10-31 Джензим Корпорейшн Фармацевтические составы на основе ингибиторов тропомиозин-родственных киназ (trk)
WO2019084285A1 (en) 2017-10-26 2019-05-02 Qian Zhao FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR
WO2019191659A1 (en) 2018-03-29 2019-10-03 Loxo Oncology, Inc. Treatment of trk-associated cancers
JP7472103B2 (ja) * 2018-08-22 2024-04-22 クルゲン（シャンハイ），インク． トロポミオシン受容体キナーゼ（ｔｒｋ）分解化合物とその使用方法
EP4110772A4 (en) 2020-02-26 2024-04-03 Cullgen (Shanghai), Inc. TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE
EP4180428A1 (en) 2021-11-12 2023-05-17 Genzyme Corporation Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions

Also Published As

Publication number Publication date
TW202334143A (zh) 2023-09-01
JP2024543413A (ja) 2024-11-21
US20250250274A1 (en) 2025-08-07
IL312625A (en) 2024-07-01
WO2023086564A1 (en) 2023-05-19
US11814383B2 (en) 2023-11-14
EP4180428A1 (en) 2023-05-17
AU2022387516A1 (en) 2024-05-23
US12291528B2 (en) 2025-05-06
EP4430043A1 (en) 2024-09-18
EP4430043A4 (en) 2025-11-05
MX2024005766A (es) 2024-07-29
US20230151008A1 (en) 2023-05-18
US20240150352A1 (en) 2024-05-09
CA3237156A1 (en) 2023-05-19

Similar Documents

Publication Publication Date Title
CN118843624A (zh) 结晶的咪唑并[4,5-b]吡啶化合物、药物组合物以及它们在治疗医学病况中的应用
CN111566095B (zh) 被取代的吡咯并吡啶jak抑制剂及其制造方法和使用方法
JP7198820B2 (ja) 置換アゼチジンジヒドロチエノピリミジンおよびホスホジエステラーゼ阻害剤としてのそれらの使用
CA2747427C (en) Method for producing diamine derivative
EP3724195B1 (en) Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
US11981681B2 (en) Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
TW201240661A (en) Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure
AU2014231722A1 (en) Salts, co-crystals, and polymorphs of an anxiolytic compound
KR20140105598A (ko) [1,2,4]트리아졸로피리딘 및 포스포디에스테라제 억제제로서의 이의 용도
JP2002504134A (ja) 疼痛を治療するためのドラフラジン類似体の使用
KR100882925B1 (ko) 세로토닌 5-ｈｔ₃ａ 길항적 효과를 갖는 피라졸 유도체함유 약제 조성물
US10391101B2 (en) Derivatives of 7-fluoro-8-chloro-5H-dibenzo [B,E,] [1,4] diazepine and use thereof
WO2009050554A2 (en) Treatment of central nervous system disorders
HUP0402357A2 (hu) Antihisztaminok alkalmazása megnövelt koponyán belüli nyomás akut csökkentésére és gyógyszerkészítmények előállítására
US20240383892A1 (en) PARTICLES OF IMIDAZO[4,5-b]PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS
HK40041147A (en) Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
HK40041147B (en) Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
HK40039957A (en) Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
HK1162467B (en) Method for producing diamine derivative

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination